| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |